

International Consortium for Harmonization of Clinical Laboratory Results
Harmonization Oversight Group / Council Meeting

DATE: 17 February 2021

TIME: 13.00 – 14.00 GMT (UK time)

HOG Member	Present	Council Member	Present
Greg Miller (chair)	x	Gary Myers (chair, AACC)	x
Eunice Lee (Vice-Chair)	x	Gye Chol Kwon (KSLM)	
Joseph Passarelli		Akira Seki (JCCLS)	
Steve Master		Sverre Sandberg (IFCC)	x
Ian Young	x	Tony Killeen (CAP)	x
Masato Maekawa			
Philippe Gillery (IFCC SD)	x		
Anja Kessler			
Melissa Snyder	x	Observer	
Yeo-Min Yun	x	Loretta Doan (AACC)	
Amrom Obstfeld		Katsuyuki Nakajima (JCCLS)	
Ross Molanaro			
YeJin Oh	x		
Huimin Wang			
Susan Copple			

Minutes:

1) Apologies were received from Joe Passarelli, Amrom Obstfeld, Steve Master, Susan Copple

2) Minutes of the previous meeting (December 16) were approved

3) Membership:

Membership remains as above.

Action: **Gary Myers to liaise with JCCLS to confirm their representative.**

4) Consideration of new measurands

a) Gentamicin – clarification to be sought on current EQA status. Note that 2003 data (ref 2) suggests low between measurement differences, but 2017 DGKL data (ref.3) suggests high between laboratory differences. True position to be clarified before confirming status.

Action: IY to ask AK about commutability of samples in DGKL scheme

IY to check for any other available data

b) Vitamin D – three documents to be combined into a single position statement and circulated (IY).

Various groups involved in standardization activities to be advised of ICHCLR position and encouraged to collaborate (IY).

c) Neisseria gonorrhoeae – agreed. Text to be added to database, clarifying that it relates to the combination of measurand and method (PCR) rather than just measurand. (IY)

d) PIVKA-II – Further EQA data required to determine current status. **Greg Miller** to see if any further information is available via joint EQALM group.

e) Tobramycin – updated information received and to be circulated by IY.

5) Current and future activities

a) Update from EQALM working group

MOU to be finalized and approved. Updates to be provided at future meeting.

b) Links with clinical societies

Information for sharing to be drafted and prepared by IY.

c) Awareness of ICHCLR role and resources

Annual / biannual newsletter to be prepared for circulation to key stakeholders and dissemination via IFCC news / AACC news etc (IY)

d) Call for programs of work to harmonize high priority measurands

ICHCLR will develop and issue a call for applications to improve the harmonization of measurands where impact would be high and status is needed. Successful applicants will be required to demonstrate a feasible plan which can be completed within a reasonable period (less than 3 years) and will achieve and maintain a satisfactory degree of harmonization. Funding will be available to support high quality applications.

In order to avoid the development of duplicate structures, discussions will be held with IFCC SD to see if this work could take place using existing IFCC mechanisms. **(IY to arrange meeting).**

6) Update on measurand list –

a) current assignments:

Urinary creatinine (Anja)

Urinary calcium (Anya)

Toxoplasma IgG (Eunice)

Apo A1 (Gary)

Apo B (Gary)

Lp(a) (Gary)

Osmolality (blood / urine) (Greg)

Quinidine (Joe)

Hepatitis A Ab IgG (Melissa)

Hepatitis A Ab IgM (Melissa)

Hepatitis A Ab (total) (Melissa)

Benzodiazepines (Ross)

CK19F (Steve)

Fetal fibronectin (Susan)

Methemoglobin (Tony – IY to check with WEQAS re any available data)

b) unallocated

51 Pre Albumin
 (Transthyretin)

53	Ammonia
63	Acetaminophen
66	Sodium (urine)
67	Haptoglobin
71	Salicylate
77	T.pallidum